CSIMarket
 
Foamix Pharmaceuticals Ltd   (FOMX)
 

FOMX reported fourth quarter of 2019 operating surplus of $37.431 millions


Published Mar 25 2023
CSIMarket Team / CSIMarket.com


Marijuana_leaf_at_Veer_Guest_House,_Manali_(164703748)For the most recent fiscal period FOMX income per share grew by 7.89 % of $0.41 per share compare to $0.38 a year ago and EPS grew by 17.14 % from $0.35 per share from the prior reporting season.

Revenues remained unaffected to $0.00 millions from $0.87 millions in the corresponding reporting season a year ago and sequentially from $0.00 millions.




Net profits of $23.161 millions in the most recent fiscal period increased by 49.62 % from net earnings of $15.480 millions reported in the most recent fiscal period a year ago. Looking further into most recent fiscal period Foamix Pharmaceuticals Ltd 's profitability, operating margin mitigated to 0%, and net margin shrank to 0%.
Operating earnings, on the other hand, improved just 48.85% to $23.199 millions.



Foamix Pharmaceuticals Ltd's Capital Expenditures Growth

Foamix Pharmaceuticals Ltd's Receivables Turnover Ratio



Other FOMX's news





Other FOMX's news





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com